Adrian Woolfson — SPARQNOW

At-a-Glance

Serves as Co-founder, President & CEO of Genyro, a company turning biology into a programmable material through AI-driven genome design and DNA construction technology.
Founder of Replay, a KKR-backed cell & gene therapy company, which was acquired by Leo Pharma in April 2026.
Led R&D programs in gene editing, in vivo genome engineering, epigenetic editing, gene therapy, and cell therapy as EVP & Head of R&D at SGMO.
Author of three critically acclaimed books, including "On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence."
Completed PhD and post-doctoral work on molecular immunology under Nobel Prize winner César Milstein.
Serves as a Board Director.

Biography

Adrian Woolfson is the Co-founder, President & CEO of Genyro, a San Diego-based company that focuses on turning biology into a programmable material. Genyro achieves this through AI-driven genome design and its Sidewinder DNA construction technology, which enables rapid, accurate, and efficient construction of complex DNA at scale. Previously, he founded Replay, a KKR-backed cell & gene therapy company, which was acquired by Leo Pharma in April 2026.